121 results on '"Lawrence HJ"'
Search Results
2. Frequent co-expression of the HOXA9 and MEIS1 homeobox genes in human myeloid leukemias
- Author
-
Lawrence, HJ, Rozenfeld, S, Cruz, C, Matsukuma, K, Kwong, A, Kömüves, L, Buchberg, AM, and Largman, C
- Published
- 1999
- Full Text
- View/download PDF
3. CYP2D6 genotype affects outcome in postmenopausal breast cancer patients treated with tamoxifen monotherapy
- Author
-
Thompson, AM, primary, Bray, S, additional, Johnson, AM, additional, Quinlan, P, additional, Nikloff, DM, additional, Evans, DG, additional, Clarke, R, additional, Lawrence, HJ, additional, Howell, A, additional, Latif, A, additional, Ferraldeschl, R, additional, Hillman, G, additional, Fontecha, M, additional, and Newman, WG, additional
- Published
- 2010
- Full Text
- View/download PDF
4. Overexpression of HOXB4 enhances the hematopoietic potential of embryonic stem cells differentiated in vitro
- Author
-
Helgason, CD, primary, Sauvageau, G, additional, Lawrence, HJ, additional, Largman, C, additional, and Humphries, RK, additional
- Published
- 1996
- Full Text
- View/download PDF
5. Homeobox genes in normal hematopoiesis and leukemia
- Author
-
Lawrence, HJ, primary and Largman, C, additional
- Published
- 1992
- Full Text
- View/download PDF
6. Erythroid-restricted expression of homeobox genes of the human HOX 2 locus
- Author
-
Mathews, CH, primary, Detmer, K, additional, Boncinelli, E, additional, Lawrence, HJ, additional, and Largman, C, additional
- Published
- 1991
- Full Text
- View/download PDF
7. Expression of retinoic acid receptor alpha mRNA in human leukemia cells
- Author
-
Largman, C, Detmer, K, Corral, JC, Hack, FM, and Lawrence, HJ
- Abstract
The expression of the newly described human retinoic acid receptor alpha (RAR alpha) in six nonlymphoid and six lymphoid leukemia cell lines and nine freshly obtained samples of leukemia cells from patients with acute nonlymphoid leukemia was assessed by Northern blot analysis, using a full length cDNA clone of RAR alpha as probe. RAR alpha was expressed in all 12 cell lines and in all fresh leukemia samples as two major transcripts of 2.6 and 3.5 kb in size. Levels of RAR alpha expression and transcript sizes in retinoid-sensitive cells (such as HL60 or fresh promyelocytic leukemia cells) were not different from those in other samples. Moreover, expression of RAR alpha was not significantly modulated by exposure to cis-retinoic acid (cisRA) in either cisRA-responsive or unresponsive cells. By using a 3' fragment of the RAR alpha gene as a probe, we confirmed that the transcripts visualized did not represent the homologous RAR beta gene. RAR alpha appears to be expressed in most human leukemia cells regardless of the type of biologic response to retinoic acid.
- Published
- 1989
- Full Text
- View/download PDF
8. cis-Retinoic acid stimulates the clonal growth of some myeloid leukemia cells in vitro
- Author
-
Lawrence, HJ, Conner, K, Kelly, MA, Haussler, MR, Wallace, P, and Bagby, GC Jr
- Abstract
We studied the effects of cis-retinoic acid (cisRA) on the clonogenic growth of samples of leukemic cells from 35 patients with acute nonlymphocytic leukemia (ANLL). We observed significant inhibition of leukemic colony growth in 17 samples by 10(-7) to 10(-6)M cisRA. However, we found that retinoid exposure resulted in striking stimulation of clonal growth in ten samples at the same drug concentrations. With the exception of cases with promyelocytic features, there was no morphologic or functional evidence that cisRA induced the leukemic blasts to differentiate. Both inhibition and stimulation were dose-dependent and observable at pharmacologically achievable levels of cisRA. Leukemic cells with monocytic features more frequently demonstrated a stimulatory response than did those without monocytic features. Depletion of T lymphocytes and monocytes did not alter the type of growth response. Assays for cellular retinoic acid- binding protein (CRABP) were performed on five samples (two with inhibitory growth responses, two with stimulatory responses, and one with no growth) and failed to reveal detectable levels of CRABP in any case. The addition of cisRA to liquid suspensions of leukemic cells produced no significant change in the number of viable cells. We conclude that the effects of cisRA on leukemic colony growth are not cytotoxic and not mediated by T lymphocytes, monocytes, or CRABP. More importantly, cisRA appears to enhance the growth of certain human leukemia cells in vitro. Taking into account the increasing use of retinoids in clinical trials for patients with leukemia, the latter findings may represent a significant cautionary note.
- Published
- 1987
- Full Text
- View/download PDF
9. Potentiation of anticoagulant effect of coumadin by 5-bromo-2?-deoxyuridine (BUDR)
- Author
-
Lawrence Hj and Oster Se
- Subjects
Pharmacology ,Cancer Research ,Anticoagulant effect ,business.industry ,medicine.drug_class ,Pharmacology toxicology ,Anticoagulant ,Long-term potentiation ,Drug interaction ,Toxicology ,Deoxyuridine ,chemistry.chemical_compound ,Oncology ,chemistry ,Oral administration ,Anesthesia ,Medicine ,Pharmacology (medical) ,business - Published
- 1988
10. Cytogenetic evidence for involvement of B lymphocytes in acquired idiopathic sideroblastic anemias
- Author
-
Lawrence, HJ, primary, Broudy, VC, additional, Magenis, RE, additional, Olson, S, additional, Tomar, D, additional, Barton, S, additional, Fitchen, JH, additional, and Bagby, GC Jr, additional
- Published
- 1987
- Full Text
- View/download PDF
11. Seventeen-year survival in multiple myeloma
- Author
-
Suyehira La and Lawrence Hj
- Subjects
Male ,medicine.medical_specialty ,Time Factors ,Osteolysis ,business.industry ,Complete remission ,Bone Neoplasms ,Hematology ,Middle Aged ,medicine.disease ,Surgery ,Lytic cycle ,Bone lesion ,Immunopathology ,medicine ,Humans ,Initial treatment ,Multiple Myeloma ,business ,Multiple myeloma - Abstract
We report a case of multiple myeloma surviving 17 years since diagnosis and 13 years in continuous complete remission since a relapse 4 years after initial treatment. Despite the prolonged remission, multiple lytic bone lesions have not healed.
- Published
- 1989
12. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.
- Author
-
Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, McArthur GA, Hutson TE, Moschos SJ, Flaherty KT, Hersey P, Kefford R, Lawrence D, Puzanov I, Lewis KD, Amaravadi RK, Chmielowski B, Lawrence HJ, Shyr Y, and Ye F
- Abstract
Background: Approximately 50% of melanomas harbor activating (V600) mutations in the serine-threonine protein kinase B-RAF (BRAF). The oral BRAF inhibitor vemurafenib (PLX4032) frequently produced tumor regressions in patients with BRAF V600-mutant metastatic melanoma in a phase 1 trial and improved overall survival in a phase 3 trial.Methods: We designed a multicenter phase 2 trial of vemurafenib in patients with previously treated BRAF V600-mutant metastatic melanoma to investigate the efficacy of vemurafenib with respect to overall response rate (percentage of treated patients with a tumor response), duration of response, and overall survival. The primary end point was the overall response rate as ascertained by the independent review committee; overall survival was a secondary end point.Results: A total of 132 patients had a median follow-up of 12.9 months (range, 0.6 to 20.1). The confirmed overall response rate was 53% (95% confidence interval [CI], 44 to 62; 6% with a complete response and 47% with a partial response), the median duration of response was 6.7 months (95% CI, 5.6 to 8.6), and the median progression-free survival was 6.8 months (95% CI, 5.6 to 8.1). Primary progression was observed in only 14% of patients. Some patients had a response after receiving vemurafenib for more than 6 months. The median overall survival was 15.9 months (95% CI, 11.6 to 18.3). The most common adverse events were grade 1 or 2 arthralgia, rash, photosensitivity, fatigue, and alopecia. Cutaneous squamous-cell carcinomas (the majority, keratoacanthoma type) were diagnosed in 26% of patients.Conclusions: Vemurafenib induces clinical responses in more than half of patients with previously treated BRAF V600-mutant metastatic melanoma. In this study with a long follow-up, the median overall survival was approximately 16 months. (Funded by Hoffmann-La Roche; ClinicalTrials.gov number, NCT00949702.). [ABSTRACT FROM AUTHOR]- Published
- 2012
- Full Text
- View/download PDF
13. A 17-Gene Genomic Prostate Score Assay Provides Independent Information on Adverse Pathology in the Setting of Combined Multiparametric Magnetic Resonance Imaging Fusion Targeted and Systematic Prostate Biopsy.
- Author
-
Salmasi A, Said J, Shindel AW, Khoshnoodi P, Felker ER, Sisk AE Jr, Grogan T, McCullough D, Bennett J, Bailey H, Lawrence HJ, Elashoff DA, Marks LS, Raman SS, Febbo PG, and Reiter RE
- Subjects
- Genomics, Humans, Image-Guided Biopsy, Magnetic Resonance Imaging methods, Male, Middle Aged, Neoplasm Grading, Predictive Value of Tests, Prostatic Neoplasms diagnostic imaging, Retrospective Studies, Risk Assessment, Prostatic Neoplasms genetics, Prostatic Neoplasms pathology
- Abstract
Purpose: Multiparametric magnetic resonance imaging and biopsy based molecular tests such as the 17-gene Oncotype DX® Genomic Prostate Score™ assay are increasingly performed to improve risk stratification in men with clinically localized prostate cancer. The prostate score assay was previously shown to be a significant independent predictor of adverse pathology findings at radical prostatectomy in men diagnosed by systematic biopsies only. Therefore, we investigated the ability of the prostate score assay to predict adverse pathology findings in the setting of magnetic resonance imaging guided prostate biopsy., Materials and Methods: We identified men diagnosed with NCCN® (National Comprehensive Cancer Network®) very low, low or intermediate risk prostate cancer who underwent simultaneous multiparametric magnetic resonance imaging fusion targeted and systematic prostate biopsy with subsequent radical prostatectomy within 6 months. Prostate score assay testing was performed on biopsy tissue with the highest Gleason score. The primary outcome of the study was adverse pathology findings, defined as Gleason score 4 + 3 or greater disease and/or pT3+ at radical prostatectomy. Independent predictors of adverse pathology findings were determined in a multivariable model to adjust for clinical parameters., Results: A total of 134 men were eligible for primary analysis. On univariable analysis the UCLA score, magnetic resonance imaging, prostate score assay results and biopsy Gleason score were significant predictors of adverse pathology findings. After multivariable adjustment prostate score assay values remained a significant predictor of adverse pathology results (prostate score assay per 20 U OR 3.28, 95% CI 1.74-6.62, p <0.001). A wide and overlapping distribution of prostate score assay results was seen across PI-RADS® (Prostate Imaging Reporting and Data System) version 2 scores., Conclusions: The prostate score assay result is an independent predictor of adverse pathology findings in patients who were diagnosed with very low, low or intermediate risk prostate cancer in the setting of multiparametric magnetic resonance imaging fusion prostate biopsy. This assay can be useful as an independent technology or an adjunct technology to multiparametric magnetic resonance imaging to individualize risk stratification of low and intermediate risk prostate cancer., (Copyright © 2018 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
14. A Biopsy-based 17-gene Genomic Prostate Score as a Predictor of Metastases and Prostate Cancer Death in Surgically Treated Men with Clinically Localized Disease.
- Author
-
Van Den Eeden SK, Lu R, Zhang N, Quesenberry CP Jr, Shan J, Han JS, Tsiatis AC, Leimpeter AD, Lawrence HJ, Febbo PG, and Presti JC
- Subjects
- Aged, Biopsy, California, Disease Progression, Humans, Male, Middle Aged, Multivariate Analysis, Neoplasm Metastasis, Predictive Value of Tests, Proportional Hazards Models, Prostatic Neoplasms mortality, Prostatic Neoplasms pathology, Registries, Retrospective Studies, Reverse Transcriptase Polymerase Chain Reaction, Risk Assessment, Risk Factors, Time Factors, Treatment Outcome, Biomarkers, Tumor genetics, Gene Expression Profiling methods, Genomics methods, Prostatectomy adverse effects, Prostatectomy mortality, Prostatic Neoplasms genetics, Prostatic Neoplasms surgery, Transcriptome
- Abstract
Background: A 17-gene biopsy-based reverse transcription polymerase chain reaction assay, which provides a Genomic Prostate Score (GPS-scale 0-100), has been validated as an independent predictor of adverse pathology and biochemical recurrence after radical prostatectomy (RP) in men with low- and intermediate-risk prostate cancer (PCa)., Objective: To evaluate GPS as a predictor of PCa metastasis and PCa-specific death (PCD) in a large cohort of men with localized PCa and long-term follow-up., Design, Setting, and Participants: A retrospective study using a stratified cohort sampling design was performed in a cohort of men treated with RP within Kaiser Permanente Northern California. RNA from archival diagnostic biopsies was assayed to generate GPS results., Outcome Measurements and Statistical Analysis: We assessed the association between GPS and time to metastasis and PCD in prespecified uni- and multivariable statistical analyses, based on Cox proportional hazard models accounting for sampling weights., Results and Limitations: The final study population consisted of 279 men with low-, intermediate-, and high-risk PCa between 1995 and 2010 (median follow-up 9.8 yr), and included 64 PCD and 79 metastases. Valid GPS results were obtained for 259 (93%). In univariable analysis, GPS was strongly associated with time to PCD, hazard ratio (HR)/20 GPS units=3.23 (95% confidence interval [CI] 1.84-5.65; p<0.001), and time to metastasis, HR/20 units=2.75 (95% CI 1.63-4.63; p<0.001). The association between GPS and both end points remained significant after adjusting for National Comprehensive Cancer Network, American Urological Association, and Cancer of the Prostate Risk Assessment (CAPRA) risks (p<0.001). No patient with low- or intermediate-risk disease and a GPS of<20 developed metastases or PCD (n=31). In receiver operating characteristic analysis of PCD at 10 yr, GPS improved the c-statistic from 0.78 (CAPRA alone) to 0.84 (GPS+CAPRA; p<0.001). A limitation of the study was that patients were treated during an era when definitive treatment was standard of care with little adoption of active surveillance., Conclusions: GPS is a strong independent predictor of long-term outcomes in clinically localized PCa in men treated with RP and may improve risk stratification for men with newly diagnosed disease., Patient Summary: Many prostate cancers are slow growing and unlikely to spread or threaten a man's life, while others are more aggressive and require treatment. Increasingly, doctors are using new molecular tests, such as the17-gene Genomic Prostate Score (GPS), which can be performed at the time of initial diagnosis to help determine how aggressive a given patient's cancer may be. In this study, performed in a large community-based healthcare network, GPS was shown to be a strong predictor as to whether a man's prostate cancer will spread and threaten his life after surgery, providing information that may help patients and their doctors decide on the best course of management of their disease., (Copyright © 2017 European Association of Urology. Published by Elsevier B.V. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
15. Association between a 17-gene genomic prostate score and multi-parametric prostate MRI in men with low and intermediate risk prostate cancer (PCa).
- Author
-
Leapman MS, Westphalen AC, Ameli N, Lawrence HJ, Febbo PG, Cooperberg MR, and Carroll PR
- Subjects
- Aged, Biopsy, Gene Expression, Humans, Male, Middle Aged, Neoplasm Grading, Neoplasm Proteins metabolism, Prostate metabolism, Prostate pathology, Prostatic Neoplasms genetics, Prostatic Neoplasms metabolism, Prostatic Neoplasms pathology, Risk, Magnetic Resonance Imaging methods, Neoplasm Proteins genetics, Prostate diagnostic imaging, Prostatic Neoplasms diagnostic imaging
- Abstract
Background: We aimed to directly compare results from multi-parametric prostate MRI (mpMRI) and a biopsy-based 17-gene RT-PCR assay providing a Genomic Prostate Score (GPS) among individuals who were candidates for active surveillance with low and intermediate risk prostate cancer (PCa)., Patients and Methods: We evaluated the association between GPS results (scale 0-100) and endorectal mpMRI findings in men with clinically localized PCa. MR studies were reviewed to a five-tier scale of increasing suspicion of malignancy. Mean apparent diffusion coefficient (ADC) was calculated from a single dominant lesion. Mean rank of the GPS (0-100) among MRI strata was compared with the Kruskal-Wallis test and Dunn's multiple comparison test. Spearman's correlation was performed to examine the association between mean ADC and scaled GPS., Results: Of 186 patients who received GPS testing, 100 were identified who received mpMRI. Mean GPS results differed between mpMRI categories (p = 0.001); however a broad range was observed in all mpMRI categories. Among men with biopsy Gleason pattern 3+3, mean GPS results were not significantly different among MRI groups (p = 0.179), but GPS differences were seen among MRI categories for patients with pattern 3+4 (p = 0.010). Mean ADC was weakly associated with GPS (σ = -0.151). Stromal response (p = 0.015) and cellular organization (p = 0.045) gene group scores differed significantly by MRI findings, but no differences were seen among androgen signaling or proliferation genes., Conclusions: Although a statistically significant association was observed between GPS results and MRI scores, a wide range of GPS values were observed across imaging categories suggesting that mpMRI and genomic profiling may offer non- overlapping clinical insights.
- Published
- 2017
- Full Text
- View/download PDF
16. Standardizing Methodology for Research with Uneven Terrains Focused on Dynamic Balance During Gait.
- Author
-
Coleman TD, Lawrence HJ, and Childers WL
- Subjects
- Biomechanical Phenomena, Female, Humans, Male, Reproducibility of Results, Young Adult, Gait physiology, Postural Balance physiology
- Abstract
This research tested a reproducible uneven walkway designed to destabilize human gait. Ten participants walked 30 times over even and uneven (7.3 × .08 m, sequentially-placed wooden blocks in a rotating pattern, 1-cm thick rubber mat) walkways. A full-body marker set and 8-camera motion capture system recorded limb kinematics. MatLab 2013b was used to calculate measures of gait stability: angular momentum, margin of stability, step width variability, CoM height, toe clearance, lateral arm swing. The minimum number of strides necessary to minimize intraparticipant variability was calculated via the interquartile range/median ratio (IMR) at 25% and 10% thresholds for each measure. A paired t test tested for significance between terrains (P < .05). The uneven walkway significantly destabilized gait as seen by increases in: coronal and sagittal plane angular momentum, step width variability, and toe clearance. We found no significant difference with the margin of stability between the 2 terrains possibly due to compensatory strategies (eg, lateral arm swing, trunk sway, step width). Recording a minimum of 10 strides per subject will keep each variable between the 25% and 10% IMR thresholds. In conclusion, the uneven walkway design significantly destabilizes human gait and at least 10 strides should be collected per subject.
- Published
- 2016
- Full Text
- View/download PDF
17. Gene expression in normal-appearing tissue adjacent to prostate cancers are predictive of clinical outcome: evidence for a biologically meaningful field effect.
- Author
-
Magi-Galluzzi C, Maddala T, Falzarano SM, Cherbavaz DB, Zhang N, Knezevic D, Febbo PG, Lee M, Lawrence HJ, and Klein EA
- Subjects
- Adult, Aged, Disease Progression, Humans, Male, Middle Aged, Neoplasm Metastasis, Neoplasm Recurrence, Local, Predictive Value of Tests, Proportional Hazards Models, Prostate pathology, Prostate surgery, Prostatectomy, Prostatic Neoplasms metabolism, Prostatic Neoplasms pathology, Prostatic Neoplasms surgery, Risk Factors, Time Factors, Treatment Outcome, Biomarkers, Tumor genetics, Gene Expression Profiling methods, Gene Expression Regulation, Neoplastic, Prostate metabolism, Prostatic Neoplasms genetics, Reverse Transcriptase Polymerase Chain Reaction, Transcriptome
- Abstract
Purpose: We evaluated gene expression in histologically normal-appearing tissue (NT) adjacent to prostate tumor in radical prostatectomy specimens, assessing for biological significance based on prediction of clinical recurrence (cR - metastatic disease or local recurrence)., Results: A total of 410 evaluable patients had paired tumor and NT. Forty-six genes, representing diverse biological pathways (androgen signaling, stromal response, stress response, cellular organization, proliferation, cell adhesion, and chromatin remodeling) were associated with cR in NT (FDR < 20%), of which 39 concordantly predicted cR in tumor (FDR < 20%). Overall GPS and its stromal response and androgen-signaling gene group components also significantly predicted time to cR in NT (RM-corrected HR/20 units = 1.25; 95% CI: 1.01-1.56; P = 0.024)., Experimental Design: Expression of 732 genes was measured by quantitative reverse transcriptase polymerase chain reaction (RT-PCR) separately in tumor and adjacent NT specimens from 127 patients with and 374 without cR following radical prostatectomy for T1/T2 prostate cancer. A 17-gene expression signature (Genomic Prostate Score [GPS]), previously validated to predict aggressive prostate cancer when measured in tumor tissue, was also assessed using pre-specified genes and algorithms. Analysis used Cox proportional hazards models, Storey's false discovery rate (FDR) control, and regression to the mean (RM) correction., Conclusions: Gene expression profiles, including GPS, from NT adjacent to tumor can predict prostate cancer outcome. These findings suggest that there is a biologically significant field effect in primary prostate cancer that is a marker for aggressive disease., Competing Interests: Dr. Klein received research support from Genomic Health, Inc. for this study. Cleveland Clinic authors received no personal compensation for the study, financial or otherwise, and do not stand to benefit financially from the publication of this study. The following authors are employees of Genomic Health and own Genomic Health, Inc. stock: Cherbavaz, Zhang, Knezevic, Febbo and Lawrence. Drs. Lee and Maddala are former employees of Genomic Health, Inc.
- Published
- 2016
- Full Text
- View/download PDF
18. Patient-specific Meta-analysis of 2 Clinical Validation Studies to Predict Pathologic Outcomes in Prostate Cancer Using the 17-Gene Genomic Prostate Score.
- Author
-
Brand TC, Zhang N, Crager MR, Maddala T, Dee A, Sesterhenn IA, Simko JP, Cooperberg MR, Srivastava S, Rosner IL, Chan JM, Febbo PG, Carroll PR, Cullen J, and Lawrence HJ
- Subjects
- Adult, Aged, Humans, Male, Middle Aged, Prognosis, Validation Studies as Topic, Genomics, Prostatic Neoplasms genetics, Prostatic Neoplasms pathology
- Abstract
Objective: To perform patient-specific meta-analysis (MA) of two independent clinical validation studies of a 17-gene biopsy-based genomic assay as a predictor of favorable pathology at radical prostatectomy., Materials and Methods: Patient-specific MA was performed on data from 2 studies (732 patients) using the Genomic Prostate Score (GPS; scale 0-100) together with Cancer of the Prostate Risk Assessment (CAPRA) score or National Comprehensive Cancer Network (NCCN) risk group as predictors of the likelihood of favorable pathology (LFP). Risk profile curves associating GPS with LFP by CAPRA score and NCCN risk group were generated. Decision curves and receiver operating characteristic curves were calculated using patient-specific MA risk estimates., Results: Patient-specific MA-generated risk profiles ensure more precise estimates of LFP with narrower confidence intervals than either study alone. GPS added significant predictive value to each clinical classifier. A model utilizing GPS and CAPRA provided the most risk discrimination. In decision-curve analysis, greater net benefit was shown when combining GPS with each clinical classifier compared with the classifier alone. The area under the receiver operating characteristic curve improved from 0.68 to 0.73 by adding GPS to CAPRA, and 0.64 to 0.70 by adding GPS to NCCN risk group. The proportion of patients with LFP >80% increased from 11% using NCCN risk group alone to 23% using GPS with NCCN. Using GPS with CAPRA identified the highest proportion-31%-of patients with LFP >80%., Conclusion: Patient-specific MA provides more precise risk estimates that reflect the complete body of evidence. GPS adds predictive value to 3 widely used clinical classifiers, and identifies a larger proportion of low-risk patients than identified by clinical risk group alone., (Copyright © 2016 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
19. The Impact of a Biopsy Based 17-Gene Genomic Prostate Score on Treatment Recommendations in Men with Newly Diagnosed Clinically Prostate Cancer Who are Candidates for Active Surveillance.
- Author
-
Badani KK, Kemeter MJ, Febbo PG, Lawrence HJ, Denes BS, Rothney MP, Rothberg MB, and Brown GA
- Abstract
Introduction: The biopsy based 17-gene GPS was clinically validated to predict the likelihood of adverse surgical pathology in men with NCCN
® very low, low or low-intermediate risk prostate cancer. We performed a prospective study to assess the impact of incorporating GPS into treatment recommendations in 3 high volume urology practices., Methods: Men with newly diagnosed prostate cancer meeting specific NCCN criteria were prospectively enrolled in the trial. Biopsy tissue was analyzed. Urologists indicated treatment recommendations on questionnaires administered before and after GPS. The primary study objectives were to assess all changes in treatment modality and/or treatment intensity after GPS., Results: A total of 158 men were included in analysis, including 35, 71 and 52 at NCCN very low, low and low-intermediate risk. Biological risk predicted by GPS differed from NCCN clinical risk alone in 61 men (39%). Overall 18% of recommendations between active surveillance and immediate treatment changed after GPS. The relative increase in recommendations for active surveillance was 24% (absolute change 41% to 51%). In 41 of 158 men (26%) modality and/or intensity recommendations changed after GPS, including 25, 14 and 2 in whom recommendation intensity decreased, increased and were equivocal, respectively. All changes were directionally consistent with GPS. The NCCN low risk group showed the greatest absolute recommendation change after GPS (37%). In 17 of 57 men (30%) the initial recommendation of radical prostatectomy was changed to active surveillance after GPS. Urologists indicated greater confidence and found that incorporating GPS was useful in 85% and 79% of cases, respectively, including when biological risk confirmed the clinical risk category., Conclusions: This study demonstrates that the 17-gene GPS influenced treatment recommendations among urologists and provided increased confidence in these recommendations in patients at NCCN very low to low-intermediate risk.- Published
- 2015
- Full Text
- View/download PDF
20. A Biopsy-based 17-gene Genomic Prostate Score Predicts Recurrence After Radical Prostatectomy and Adverse Surgical Pathology in a Racially Diverse Population of Men with Clinically Low- and Intermediate-risk Prostate Cancer.
- Author
-
Cullen J, Rosner IL, Brand TC, Zhang N, Tsiatis AC, Moncur J, Ali A, Chen Y, Knezevic D, Maddala T, Lawrence HJ, Febbo PG, Srivastava S, Sesterhenn IA, and McLeod DG
- Subjects
- Adult, Black or African American genetics, Aged, Biopsy, Large-Core Needle, Cohort Studies, Genomics, Humans, Logistic Models, Male, Middle Aged, Neoplasm Recurrence, Local pathology, Prognosis, Proportional Hazards Models, Prostatectomy, Prostatic Neoplasms pathology, Prostatic Neoplasms surgery, Risk Assessment, White People genetics, Biomarkers, Tumor genetics, Gene Expression Regulation, Neoplastic, Neoplasm Recurrence, Local genetics, Prostatic Neoplasms genetics
- Abstract
Background: Biomarkers that are validated in independent cohorts are needed to improve risk assessment for prostate cancer (PCa)., Objective: A racially diverse cohort of men (20% African American [AA]) was used to evaluate the association of the clinically validated 17-gene Genomic Prostate Score (GPS) with recurrence after radical prostatectomy and adverse pathology (AP) at surgery., Design, Setting, and Participants: Biopsies from 431 men treated for National Comprehensive Cancer Network (NCCN) very low-, low-, or intermediate-risk PCa between 1990 and 2011 at two US military medical centers were tested to validate the association between GPS and biochemical recurrence (BCR) and to confirm the association with AP. Metastatic recurrence (MR) was also evaluated., Outcome Measurements and Statistical Analysis: Cox proportional hazards models were used for BCR and MR, and logistic regression was used for AP. Central pathology review was performed by one uropathologist. AP was defined as primary Gleason pattern 4 or any pattern 5 and/or pT3 disease., Results and Limitations: GPS results (scale: 0-100) were obtained in 402 cases (93%); 62 men (15%) experienced BCR, 5 developed metastases, and 163 had AP. Median follow-up was 5.2 yr. GPS predicted time to BCR in univariable analysis (hazard ratio per 20 GPS units [HR/20 units]: 2.9; p<0.001) and after adjusting for NCCN risk group (HR/20 units: 2.7; p<0.001). GPS also predicted time to metastases (HR/20 units: 3.8; p=0.032), although the event rate was low (n=5). GPS was strongly associated with AP (odds ratio per 20 GPS units: 3.3; p<0.001), adjusted for NCCN risk group. In AA and Caucasian men, the median GPS was 30.3 for both, the distributions of GPS results were similar, and GPS was similarly predictive of outcome., Conclusions: The association of GPS with near- and long-term clinical end points establishes the assay as a strong independent measure of PCa aggressiveness. Tumor aggressiveness, as measured by GPS, and outcomes were similar in AA and Caucasian men in this equal-access health care system., Patient Summary: Predicting outcomes in men with newly diagnosed prostate cancer is challenging. This study demonstrates that a new molecular test, the Genomic Prostate Score, which can be performed on a patient's original prostate needle biopsy, can predict the aggressiveness of the cancer and help men make decisions regarding the need for immediate treatment of their cancer., (Copyright © 2014 European Association of Urology. Published by Elsevier B.V. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
21. Clinical validation of a PCR assay for the detection of EGFR mutations in non-small-cell lung cancer: retrospective testing of specimens from the EURTAC trial.
- Author
-
Benlloch S, Botero ML, Beltran-Alamillo J, Mayo C, Gimenez-Capitán A, de Aguirre I, Queralt C, Ramirez JL, Ramón y Cajal S, Klughammer B, Schlegel M, Bordogna W, Chen D, Zhang G, Kovach B, Shieh F, Palma JF, Wu L, Lawrence HJ, and Taron M
- Subjects
- Carcinoma, Non-Small-Cell Lung drug therapy, Erlotinib Hydrochloride, Female, Humans, Lung Neoplasms drug therapy, Male, Middle Aged, Mutation genetics, Polymerase Chain Reaction methods, Prospective Studies, Protein Kinase Inhibitors therapeutic use, Quinazolines therapeutic use, Retrospective Studies, Sequence Analysis, DNA methods, Carcinoma, Non-Small-Cell Lung diagnosis, Carcinoma, Non-Small-Cell Lung genetics, ErbB Receptors genetics, Lung Neoplasms diagnosis, Lung Neoplasms genetics
- Abstract
The EURTAC trial demonstrated that the tyrosine kinase inhibitor (TKI) erlotinib was superior to chemotherapy as first-line therapy for advanced non-small cell lung cancers (NSCLC) that harbor EGFR activating mutations in a predominantly Caucasian population. Based on EURTAC and several Asian trials, anti-EGFR TKIs are standard of care for EGFR mutation-positive NSCLC. We sought to validate a rapid multiplex EGFR mutation assay as a companion diagnostic assay to select patients for this therapy. Samples from the EURTAC trial were prospectively screened for EGFR mutations using a combination of laboratory-developed tests (LDTs), and tested retrospectively with the cobas EGFR mutation test (EGFR PCR test). The EGFR PCR test results were compared to the original LDT results and to Sanger sequencing, using a subset of specimens from patients screened for the trial. Residual tissue was available from 487 (47%) of the 1044 patients screened for the trial. The EGFR PCR test showed high concordance with LDT results with a 96.3% overall agreement. The clinical outcome of patients who were EGFR-mutation detected by the EGFR PCR test was very similar to the entire EURTAC cohort. The concordance between the EGFR PCR test and Sanger sequencing was 90.6%. In 78.9% of the discordant samples, the EGFR PCR test result was confirmed by a sensitive deep sequencing assay. This retrospective study demonstrates the clinical utility of the EGFR PCR test in the accurate selection of patients for anti-EGFR TKI therapy. The EGFR PCR test demonstrated improved performance relative to Sanger sequencing.
- Published
- 2014
- Full Text
- View/download PDF
22. A guide for clinicians in the evaluation of emerging molecular diagnostics for newly diagnosed prostate cancer.
- Author
-
Canfield SE, Kibel AS, Kemeter MJ, Febbo PG, Lawrence HJ, and Moul JW
- Abstract
Prostate-specific antigen (PSA) screening is associated with a decline in prostate cancer-related mortality. However, screening has also led to overdiagnosis and overtreatment of clinically insignificant tumors. Recently, certain national guidelines (eg, US Preventive Services Task Force) have recommended against PSA screening, which may lead to a reverse-stage migration. Although many prostate tumors are indolent at presentation, others are aggressive and are appropriate targets for treatment interventions. Utilization of molecular markers may improve our ability to measure tumor biology and allow better discrimination of indolent and aggressive tumors at diagnosis. Many emerging commercial molecular diagnostic assays have been designed to provide more accurate risk stratification for newly diagnosed prostate cancer. Unfamiliarity with molecular diagnostics may make it challenging for some clinicians to navigate and interpret the medical literature to ascertain whether particular assays are appropriately developed and validated for clinical use. Herein, the authors provide a framework for practitioners to use when assessing new tissue-based molecular assays. This review outlines aspects of assay development, clinical and analytic validation and clinical utility studies, and regulatory issues, which collectively determine whether tests (1) are actionable for specific clinical indications, (2) measurably influence treatment decisions, and (3) are sufficiently validated to warrant incorporation into clinical practice.
- Published
- 2014
23. Comparison of molecular testing methods for the detection of EGFR mutations in formalin-fixed paraffin-embedded tissue specimens of non-small cell lung cancer.
- Author
-
Lopez-Rios F, Angulo B, Gomez B, Mair D, Martinez R, Conde E, Shieh F, Tsai J, Vaks J, Current R, Lawrence HJ, and Gonzalez de Castro D
- Subjects
- Formaldehyde, Humans, Paraffin Embedding, Reproducibility of Results, Tissue Fixation, Carcinoma, Non-Small-Cell Lung genetics, Genes, erbB-1 genetics, Genetic Techniques, Lung Neoplasms genetics, Mutation
- Abstract
Aim: To conduct a methods correlation study of three different assays for the detection of mutations at EGFR gene in human formalin-fixed paraffin-embedded tumour (FFPET) specimens of non-small cell lung carcinomas (NSCLC)., Methods: We conducted a 2-site method comparison study of two european conformity (CE) in vitro diagnostic (IVD)-marked assays, the cobas EGFR Mutation Test and the Therascreen EGFR29 Mutation Kit, and 2× bidirectional Sanger sequencing. We blind-tested 124 NSCLC FFPET specimens with all three methods; the cobas test was performed at both sites. Positive (PPA) and negative percent agreements (NPA) were determined for the cobas test versus each of the other two methods. Specimens yielding discordant test results between methods were further tested using quantitative massively parallel pyrosequencing (MPP)., Results: PPA between cobas and Sanger was 98.8%; NPA was 79.3%. Overall there were seven discordant results. MPP confirmed an exon 19 deletion in two cases and L858R mutation in four cases. PPA between cobas and Therascreen was 98.9% and NPA was 100%. There was one discordant result. Reproducibility of the cobas test between the two sites was 99.2%., Conclusions: The invalid rates for the cobas test and Therascreen were lower than Sanger sequencing. The cobas and Therascreen assays showed a high degree of concordance, and both were more sensitive for the detection of exon 19 deletion and L858R mutations than Sanger. The cobas test was highly reproducible between the two testing sites, used the least amount of DNA input and was the only test with automated results reporting.
- Published
- 2013
- Full Text
- View/download PDF
24. Analytic performance studies and clinical reproducibility of a real-time PCR assay for the detection of epidermal growth factor receptor gene mutations in formalin-fixed paraffin-embedded tissue specimens of non-small cell lung cancer.
- Author
-
O'Donnell P, Ferguson J, Shyu J, Current R, Rehage T, Tsai J, Christensen M, Tran HB, Chien SS, Shieh F, Wei W, Lawrence HJ, Wu L, Schilling R, Bloom K, Maltzman W, Anderson S, and Soviero S
- Subjects
- Exons, Humans, Limit of Detection, Molecular Diagnostic Techniques, Multiplex Polymerase Chain Reaction, Paraffin Embedding, Reproducibility of Results, Carcinoma, Non-Small-Cell Lung genetics, DNA Mutational Analysis methods, ErbB Receptors genetics, Lung Neoplasms genetics, Mutation, Real-Time Polymerase Chain Reaction
- Abstract
Background: Epidermal growth factor receptor (EGFR) gene mutations identify patients with non-small cell lung cancer (NSCLC) who have a high likelihood of benefiting from treatment with anti-EGFR tyrosine kinase inhibitors. Sanger sequencing is widely used for mutation detection but can be technically challenging, resulting in longer turn-around-time, with limited sensitivity for low levels of mutations. This manuscript details the technical performance verification studies and external clinical reproducibility studies of the cobas EGFR Mutation Test, a rapid multiplex real-time PCR assay designed to detect 41 mutations in exons 18, 19, 20 and 21., Methods: The assay's limit of detection was determined using 25 formalin-fixed paraffin-embedded tissue (FFPET)-derived and plasmid DNA blends. Assay performance for a panel of 201 specimens was compared against Sanger sequencing with resolution of discordant specimens by quantitative massively parallel pyrosequencing (MPP). Internal and external reproducibility was assessed using specimens tested in duplicate by different operators, using different reagent lots, instruments and at different sites. The effects on the performance of the cobas EGFR test of endogenous substances and nine therapeutic drugs were evaluated in ten FFPET specimens. Other tests included an evaluation of the effects of necrosis, micro-organisms and homologous DNA sequences on assay performance, and the inclusivity of the assay for less frequent mutations., Results: A >95% hit rate was obtained in blends with >5% mutant alleles, as determined by MPP analysis, at a total DNA input of 150 ng. The overall percent agreement between Sanger sequencing and the cobas test was 96.7% (negative percent agreement 97.5%; positive percent agreement 95.8%). Assay repeatability was 98% when tested with two operators, instruments, and reagent lots. In the external reproducibility study, the agreement was > 99% across all sites, all operators and all reagent lots for 11/12 tumors tested. Test performance was not compromised by endogenous substances, therapeutic drugs, necrosis up to 85%, and common micro-organisms. All of the assessed less common mutations except one (exon 19 deletion mutation 2236_2248 > AGAC) were detected at a similar DNA input level as that for the corresponding predominant mutation., Conclusion: The cobas EGFR Mutation Test is a sensitive, accurate, rapid, and reproducible assay.
- Published
- 2013
- Full Text
- View/download PDF
25. Comparison of testing methods for the detection of BRAF V600E mutations in malignant melanoma: pre-approval validation study of the companion diagnostic test for vemurafenib.
- Author
-
Lopez-Rios F, Angulo B, Gomez B, Mair D, Martinez R, Conde E, Shieh F, Vaks J, Langland R, Lawrence HJ, and de Castro DG
- Subjects
- Humans, Indoles pharmacology, Melanoma pathology, Reproducibility of Results, Reverse Transcriptase Polymerase Chain Reaction, Sulfonamides pharmacology, Vemurafenib, DNA Mutational Analysis methods, Diagnostic Tests, Routine methods, Indoles therapeutic use, Melanoma drug therapy, Melanoma genetics, Mutation genetics, Proto-Oncogene Proteins B-raf genetics, Sulfonamides therapeutic use
- Abstract
Background: The cobas 4800 BRAF V600 Mutation Test is a CE-marked and FDA-approved in vitro diagnostic assay used to select patients with metastatic melanoma for treatment with the selective BRAF inhibitor vemurafenib. We describe the pre-approval validation of this test in two external laboratories., Methods: Melanoma specimens were tested for BRAF V600 mutations at two laboratories with the: cobas BRAF Mutation Test; ABI BRAF test; and bidirectional direct sequencing. Positive (PPA) and negative (NPA) percent agreements were determined between the cobas test and the other assays. Specimens with discordant results were tested with massively parallel pyrosequencing (454). DNA blends with 5% mutant alleles were tested to assess detection rates., Results: Invalid results were observed in 8/116 specimens (6·9%) with Sanger, 10/116 (8·6%) with ABI BRAF, and 0/232 (0%) with the cobas BRAF test. PPA was 97·7% for V600E mutation for the cobas BRAF test and Sanger, and NPA was 95·3%. For the cobas BRAF test and ABI BRAF, PPA was 71·9% and NPA 83·7%. For 16 cobas BRAF test-negative/ABI BRAF-positive specimens, 454 sequencing detected no codon 600 mutations in 12 and variant codon 600 mutations in four. For eight cobas BRAF test-positive/ABI BRAF-negative specimens, four were V600E and four V600K by 454 sequencing. Detection rates for 5% mutation blends were 100% for the cobas BRAF test, 33% for Sanger, and 21% for the ABI BRAF. Reproducibility of the cobas BRAF test was 111/116 (96%) between the two sites., Conclusions: It is feasible to evaluate potential companion diagnostic tests in external laboratories simultaneously to the pivotal clinical trial validation. The health authority approved assay had substantially better performance characteristics than the two other methods. The overall success of the cobas BRAF test is a proof of concept for future biomarker development.
- Published
- 2013
- Full Text
- View/download PDF
26. Multisite analytic performance studies of a real-time polymerase chain reaction assay for the detection of BRAF V600E mutations in formalin-fixed, paraffin-embedded tissue specimens of malignant melanoma.
- Author
-
Anderson S, Bloom KJ, Vallera DU, Rueschoff J, Meldrum C, Schilling R, Kovach B, Lee JR, Ochoa P, Langland R, Halait H, Lawrence HJ, and Dugan MC
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Amino Acid Substitution, Female, Formaldehyde, Humans, Indoles therapeutic use, Male, Melanoma drug therapy, Melanoma pathology, Melanoma secondary, Middle Aged, Paraffin Embedding, Protein Kinase Inhibitors therapeutic use, Proto-Oncogene Proteins B-raf antagonists & inhibitors, Reproducibility of Results, Sulfonamides therapeutic use, Tissue Fixation, Vemurafenib, Young Adult, DNA Mutational Analysis methods, Melanoma genetics, Mutation, Missense, Proto-Oncogene Proteins B-raf genetics, Real-Time Polymerase Chain Reaction methods
- Abstract
Context: A polymerase chain reaction-based companion diagnostic (cobas 4800 BRAF V600 Mutation Test) was recently approved by the US Food and Drug Administration to select patients with BRAF-mutant metastatic melanoma for treatment with the BRAF inhibitor vemurafenib., Objectives: (1) To compare the analytic performance of the cobas test to Sanger sequencing by using screening specimens from phase II and phase III trials of vemurafenib, and (2) to assess the reproducibility of the cobas test at different testing sites., Design: Specimens from 477 patients were used to determine positive and negative percent agreements between the cobas test and Sanger sequencing for detecting V600E (1799T>A) mutations. Specimens were evaluated with a massively parallel pyrosequencing method (454) to resolve discordances between polymerase chain reaction and Sanger results. Reproducibility of the cobas test was assessed at 3 sites by using 3 reagent lots and an 8-member panel of melanoma samples., Results: A valid cobas result was obtained for all eligible patients. Sanger sequencing had a failure rate of 9.2% (44 of 477). For the remaining 433 specimens, positive percent agreement was 96.4% (215 of 223) and negative percent agreement, 80% (168 of 210). Among 42 cobas mutation-positive/Sanger V600E-negative specimens, 17 were V600E positive and 24 were V600K positive by 454. The cobas test detected 70% of V600K mutations. In the reproducibility study, a correct interpretation was made for 100% of wild-type specimens and specimens with greater than 5% mutant alleles; V600E mutations were detected in 90% of specimens with less than 5% mutant alleles., Conclusions: The cobas test (1) had a lower assay failure rate than that of Sanger, (2) was more sensitive in detecting V600E mutations, (3) detected most V600K mutations, and (4) was highly reproducible.
- Published
- 2012
- Full Text
- View/download PDF
27. A comparison of three methods for detecting KRAS mutations in formalin-fixed colorectal cancer specimens.
- Author
-
Gonzalez de Castro D, Angulo B, Gomez B, Mair D, Martinez R, Suarez-Gauthier A, Shieh F, Velez M, Brophy VH, Lawrence HJ, and Lopez-Rios F
- Subjects
- Adult, Aged, Aged, 80 and over, Colorectal Neoplasms pathology, Female, Formaldehyde, Humans, Male, Middle Aged, Proto-Oncogene Proteins p21(ras), Reproducibility of Results, Sequence Analysis, DNA, Tissue Fixation, Colorectal Neoplasms genetics, Mutation, Proto-Oncogene Proteins genetics, ras Proteins genetics
- Abstract
Background: KRAS mutation testing is required to select patients with metastatic colorectal cancer (CRC) to receive anti-epidermal growth factor receptor antibodies, but the optimal KRAS mutation test method is uncertain., Methods: We conducted a two-site comparison of two commercial KRAS mutation kits - the cobas KRAS Mutation Test and the Qiagen therascreen KRAS Kit - and Sanger sequencing. A panel of 120 CRC specimens was tested with all three methods. The agreement between the cobas test and each of the other methods was assessed. Specimens with discordant results were subjected to quantitative massively parallel pyrosequencing (MPP). DNA blends were tested to determine detection rates at 5% mutant alleles., Results: Reproducibility of the cobas test between sites was 98%. Six mutations were detected by cobas that were not detected by Sanger, and five were confirmed by MPP. The cobas test detected eight mutations which were not detected by the therascreen test, and seven were confirmed by MPP. Detection rates with 5% mutant DNA blends were 100% for the cobas and therascreen tests and 19% for Sanger., Conclusion: The cobas test was reproducible between sites, and detected several mutations that were not detected by the therascreen test or Sanger. Sanger sequencing had poor sensitivity for low levels of mutation.
- Published
- 2012
- Full Text
- View/download PDF
28. Analytical performance of a real-time PCR-based assay for V600 mutations in the BRAF gene, used as the companion diagnostic test for the novel BRAF inhibitor vemurafenib in metastatic melanoma.
- Author
-
Halait H, Demartin K, Shah S, Soviero S, Langland R, Cheng S, Hillman G, Wu L, and Lawrence HJ
- Subjects
- Cell Line, Tumor, DNA Mutational Analysis methods, Formaldehyde, Humans, Melanoma drug therapy, Melanoma secondary, Paraffin Embedding, Patient Selection, Predictive Value of Tests, Proto-Oncogene Proteins B-raf antagonists & inhibitors, Proto-Oncogene Proteins B-raf metabolism, Reproducibility of Results, Skin Neoplasms drug therapy, Skin Neoplasms pathology, Tissue Fixation, Vemurafenib, DNA, Neoplasm analysis, Indoles therapeutic use, Melanoma genetics, Mutation, Proto-Oncogene Proteins B-raf genetics, Real-Time Polymerase Chain Reaction methods, Skin Neoplasms genetics, Sulfonamides therapeutic use
- Abstract
Melanomas frequently harbor BRAFV600 mutations. Vemurafenib (RG7204/PLX4032), a small-molecule inhibitor of mutant BRAF, has shown striking clinical efficacy in BRAFV600 mutant melanoma, creating the need for a well-validated companion diagnostic to select patients for treatment. We describe analytic performance characteristics of the cobas 4800 BRAF V600 Mutation Test, the test used to select patients for the pivotal vemurafenib trials. This real-time polymerase chain reaction assay was designed to detect the V600E (1799T>A) mutation DNA from formalin-fixed paraffin-embedded tissue samples. Sensitivity was assessed using blends of cell lines or tumor DNA, and tumor specimens with low levels of mutant alleles, as determined by 454 sequencing (a quantitative next-generation pyrosequencing method). A >96% hit rate was obtained across all specimen types with 5% mutant alleles at a DNA input of 125 ng, an amount readily obtained from one 5-μm section. The cobas test showed a higher sensitivity and specificity than direct bidirectional sequencing in a panel of 219 melanoma specimens. Cross reactivity with V600K and V600D was observed. Repeated testing of 5 specimens by 2 operators, using different instruments and reagent lots, yielded correct calls in 158/160 tests (98.8%). A set of 26 highly pigmented samples were identified that gave invalid test results. A simple 1:2 dilution resulted in a valid test result of 76% in such cases. The cobas test is a reproducible assay that detects some non-V600E mutations and is more accurate than direct sequencing in detecting BRAFV600E.
- Published
- 2012
- Full Text
- View/download PDF
29. Analytical performance of a PCR assay for the detection of KRAS mutations (codons 12/13 and 61) in formalin-fixed paraffin-embedded tissue samples of colorectal carcinoma.
- Author
-
Lee S, Brophy VH, Cao J, Velez M, Hoeppner C, Soviero S, and Lawrence HJ
- Subjects
- DNA, Neoplasm analysis, DNA, Neoplasm genetics, Formaldehyde, Humans, Paraffin Embedding, Proto-Oncogene Proteins p21(ras), Reproducibility of Results, Sensitivity and Specificity, Tissue Fixation, Adenocarcinoma genetics, Colorectal Neoplasms genetics, DNA Mutational Analysis methods, Polymerase Chain Reaction methods, Proto-Oncogene Proteins genetics, ras Proteins genetics
- Abstract
KRAS mutation testing is mandatory before prescribing anti-epidermal growth factor monoclonal antibodies in the treatment of advanced colorectal cancer. We describe the performance of a TaqMelt polymerase chain reaction (PCR) assay-the cobas® KRAS Mutation Test-designed to detect 19 mutations in codons 12, 13, and 61. The limit of detection was determined using DNA blends from cell lines, plasmids, and formalin-fixed paraffin-embedded tissue specimens. Assay performance was compared to Sanger sequencing using a panel of 188 specimens. Discordant specimens were subjected to next generation pyrosequencing (454). Assay repeatability was assessed using a panel of six specimens. A >95% correct mutation call rate was obtained in all specimen types with ~5% mutant alleles at DNA inputs of 0.8-6.3 ng per PCR reaction; 100% detection rate was observed at the recommended DNA input of 50 ng. The positive percent agreement with Sanger was 97.5% (79/81) for codons 12/13 and 85.7% (6/7) for codon 61. Negative percent agreement was 94.4% (101/107) for codon 12/13 and 99.4% (180/181) for codon 61. Nine of 10 discordant specimens yielded 454 results consistent with the cobas® results. With repeated testing, the assay showed a correct call rate of 100% (192/192) for all operators, instruments, reagent lots, and days tested. The cobas® test detects KRAS mutations in codons 12, 13, and 61 at a limit of detection of <5%. The PCR assay was more sensitive and specific than Sanger sequencing, and performance was highly reproducible. Test performance was not influenced by various endogenous interfering substances or common gut microbes.
- Published
- 2012
- Full Text
- View/download PDF
30. Pharmacogenetic testing affects choice of therapy among women considering tamoxifen treatment.
- Author
-
Lorizio W, Rugo H, Beattie MS, Tchu S, Melese T, Melisko M, Wu AH, Lawrence HJ, Nikoloff M, and Ziv E
- Abstract
Background: Pharmacogenetic testing holds major promise in allowing physicians to tailor therapy to patients based on genotype. However, there is little data on the impact of pharmacogenetic test results on patient and clinician choice of therapy. CYP2D6 testing among tamoxifen users offers a potential test case of the use of pharmacogenetic testing in the clinic. We evaluated the effect of CYP2D6 testing in clinical practice to determine whether genotype results affected choice of hormone therapy in a prospective cohort study., Methods: Women planning to take or currently taking tamoxifen were considered eligible. Participants were enrolled in an informational session that reviewed the results of studies of CYP2D6 genotype on breast cancer recurrence. CYP2D6 genotyping was offered to participants using the AmpliChip CYP450 Test. Women were classified as either poor, intermediate, extensive or ultra-rapid metabolizers. Results were provided to clinicians without specific treatment recommendations. Follow-up was performed with a structured phone interview 3 to 6 months after testing to evaluate changes in medication., Results: A total of 245 women were tested and 235 completed the follow-up survey. Six of 13 (46%) women classified as poor metabolizers reported changing treatment compared with 11 of 218 (5%) classified as intermediate, extensive or ultra-rapid metabolizers (P < 0.001). There was no difference in treatment choices between women classified as intermediate and extensive metabolizers. In multi-variate models that adjusted for age, race/ethnicity, educational status, method of referral into the study, prior knowledge of CYP2D6 testing, the patients' CYP2D6 genotype was the only significant factor that predicted a change in therapy (odds ratio 22.8; 95% confidence interval 5.2 to 98.8). Genetic testing did not affect use of co-medications that interact with CYP2D6., Conclusions: CYP2D6 genotype testing led to changes in therapy among poor metabolizers, even in the absence of definitive data that an alternative medicine improved outcomes. Pharmacogenetic testing can affect choice of therapy, even in the absence of definitive data on clinical impact.
- Published
- 2011
- Full Text
- View/download PDF
31. Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes.
- Author
-
Madlensky L, Natarajan L, Tchu S, Pu M, Mortimer J, Flatt SW, Nikoloff DM, Hillman G, Fontecha MR, Lawrence HJ, Parker BA, Wu AH, and Pierce JP
- Subjects
- Breast Neoplasms drug therapy, Cohort Studies, Female, Genotype, Humans, Middle Aged, Phenotype, Tamoxifen blood, Tamoxifen therapeutic use, Treatment Outcome, Breast Neoplasms enzymology, Breast Neoplasms genetics, Cytochrome P-450 CYP2D6 genetics, Tamoxifen analogs & derivatives, Tamoxifen metabolism
- Abstract
We explored whether breast cancer outcomes are associated with endoxifen and other metabolites of tamoxifen and examined potential correlates of endoxifen concentration levels in serum including cytochrome P450 2D6 (CYP2D6) metabolizer phenotype and body mass index (BMI). Concentration levels of tamoxifen, endoxifen, 4-hydroxytamoxifen (4OH-tamoxifen), and N-desmethyltamoxifen (ND-tamoxifen) were measured from samples taken from 1,370 patients with estrogen receptor (ER)-positive breast cancer who were participating in the Women's Healthy Eating and Living (WHEL) Study. We tested these concentration levels for possible associations with breast cancer outcomes and found that breast cancer outcomes were not associated with the concentration levels of tamoxifen, 4-hydroxytamoxifen, and ND-tamoxifen. For endoxifen, a threshold was identified, with women in the upper four quintiles of endoxifen concentration appearing to have a 26% lower recurrence rate than women in the bottom quintile (hazard ratio (HR) = 0.74; 95% confidence interval (CI), (0.55-1.00)). The predictors of this higher-risk bottom quintile were poor/intermediate metabolizer genotype, higher BMI, and lower tamoxifen concentrations as compared with the mean for the cohort as a whole. This study suggests that there is a minimal concentration threshold above which endoxifen is effective against the recurrence of breast cancer and that ~80% of tamoxifen takers attain this threshold.
- Published
- 2011
- Full Text
- View/download PDF
32. Transit-amplifying cell frequency and cell cycle kinetics are altered in aged epidermis.
- Author
-
Charruyer A, Barland CO, Yue L, Wessendorf HB, Lu Y, Lawrence HJ, Mancianti ML, and Ghadially R
- Subjects
- Age Factors, Animals, Cell Differentiation physiology, Cell Division physiology, Cells, Cultured, Flow Cytometry, G1 Phase physiology, Green Fluorescent Proteins genetics, Mice, Mice, Inbred C57BL, Mice, SCID, Mice, Transgenic, S Phase physiology, Stem Cells cytology, Stem Cells physiology, Epidermal Cells, Epidermis physiology, Skin Aging pathology, Skin Aging physiology
- Abstract
Aged epidermis is less proliferative than young, as exemplified by slower wound healing. However, it is not known whether quantitative and/or qualitative alterations in the stem and/or transit-amplifying (TA) compartments are responsible for the decreased proliferation. Earlier studies found a normal or decreased frequency of putative epidermal stem cells (EpiSCs) with aging. We show, using long-term repopulation in vivo and colony formation in vitro, that, although no significant difference was detected in EpiSC frequency with aging, TA cell frequency is increased. Moreover, aged TA cells persist longer, whereas their younger counterparts have already differentiated. Underlying the alteration in TA cell kinetics in the aged is an increase in the proportion of cycling keratinocytes, as well as an increase in cell cycle duration. In summary, although no significant difference in EpiSC frequency was found, TA cell frequency was increased (as measured by in vivo repopulation, growth fraction, and colony formation). Furthermore, the proliferative capacity (cellular output) of individual aged EpiSCs and TA cells was decreased compared to that of young cells. Although longer cell cycle duration contributes to the decreased proliferative output from aged progenitors, the greater number of TA cells may be a compensatory mechanism tending to offset this deficit.
- Published
- 2009
- Full Text
- View/download PDF
33. Rapid adhesion to collagen isolates murine keratinocytes with limited long-term repopulating ability in vivo despite high clonogenicity in vitro.
- Author
-
Strachan LR, Scalapino KJ, Lawrence HJ, and Ghadially R
- Subjects
- Animals, Cell Adhesion physiology, Cell Proliferation, Clone Cells, Colony-Forming Units Assay, Flow Cytometry, In Vitro Techniques, Mice, Mice, Inbred C57BL, Mice, Transgenic, Skin cytology, Time, Collagen metabolism, Keratinocytes cytology, Keratinocytes metabolism, Stem Cells cytology, Stem Cells metabolism
- Abstract
A prevalent belief in epidermal biology is that stem cells are highly clonogenic; that is, they have the ability to produce many large colonies in vitro. However, it has been well-established in hematology, and recently suggested in epithelial biology, that short-term in vitro clonogenic assays may not be reliable predictors of long-term in vivo repopulating ability. Numerous groups have shown that rapid adhesion to collagen selects for highly clonogenic keratinocytes, but it has not been demonstrated whether this subpopulation is enriched in stem cells as defined by long-term repopulating ability in vivo. We found that although rapid adhesion to collagen (within 5 minutes) selected for cells with increased short-term colony forming ability in vitro, these cells were not enriched in long-term proliferative ability in vitro or in repopulating ability in vivo after 9 weeks. Conversely, keratinocytes that did not adhere to collagen (after 20 minutes) were less clonogenic in short-term assays but possessed equivalent long-term proliferative ability in vitro and superior long-term repopulating ability in vivo. Both the rapidly adherent cell and not rapidly adherent cell populations contained small, noncomplex basaloid cells, expressed integrin alpha2 (a collagen IV receptor), and expressed the putative epidermal stem cell phenotype integrin alpha6(hi)CD71(lo). Our results indicate that the superior short-term colony forming ability of collagen-adherent murine keratinocytes does not correlate with long-term repopulating ability in vitro or in vivo and that proliferation in vitro is not a reliable surrogate for stem cell behavior in vivo.
- Published
- 2008
- Full Text
- View/download PDF
34. Nucleophosmin mutations in acute myeloid leukemia in children.
- Author
-
Lawrence HJ
- Subjects
- Acute Disease, Child, Humans, Mutation, Nucleophosmin, Leukemia, Myeloid genetics, Nuclear Proteins genetics
- Published
- 2007
- Full Text
- View/download PDF
35. Hoxa9/hoxb3/hoxb4 compound null mice display severe hematopoietic defects.
- Author
-
Magnusson M, Brun AC, Lawrence HJ, and Karlsson S
- Subjects
- Animals, Body Weight, Cell Lineage, Hematopoietic System pathology, Homeodomain Proteins genetics, Leukocytes, Mononuclear pathology, Mice, Mice, Knockout, Mutation, Organ Size, Spleen anatomy & histology, Spleen cytology, Transcription Factors genetics, Hematopoietic System abnormalities, Homeodomain Proteins physiology, Transcription Factors physiology
- Abstract
Objective: Members of the hox family of homeodomain-containing transcription factors, including hoxa9, hoxb3, and hoxb4 play an important role in the regulation of differentiation, proliferation and self-renewal of hematopoietic stem and progenitor cells. Lack-of-function studies using hoxa9, hoxb4, or hoxb3/hoxb4 null mice demonstrate that all these mutations compromise the repopulating ability of hematopoietic stem cells (HSC), implying similar functions of each of these genes in hematopoiesis. Because cross regulation and cooperativity are known features of hox proteins, we investigated mice with a compound deficiency in hoxa9, hoxb3 and hoxb4 (hoxa9/b3/b4) for evidence of synergy between these genes in hematopoiesis., Materials and Methods: Hoxa9/b3/b4 were generated by mating the hoxb3/hoxb4 null mice with the hoxa9 null strain and HSC function was measured by competitive repopulating assay and by immunophenotype using fluorescence-activated cell sorting., Results: Our findings demonstrate that the hoxa9/b3/b4 null mice are smaller in body weight, and display a marked reduction in spleen size and cellularity compared to control mice. The numbers of colony-forming unit (CFU)-granulocyte macrophage and CFU-spleen progenitor colonies were normal but hoxa9/b3/b4 null bone marrow contained increased numbers of immunophenotypic HSC (Lin(-), c-kit(+), Sca-1(+), CD150(+)). However the reconstitution defect in hoxa9 null HSC was not enhanced further in the hoxa9/b3/b4 null HSC., Conclusion: These findings demonstrate overlapping functions of hoxa9, hoxb3, and hoxb4 in hematopoietic cells, and emphasize an important role for these transcription factors for regulation of HSC proliferation. However, none of these hox proteins is absolutely essential for generation or maintenance of all major blood lineages.
- Published
- 2007
- Full Text
- View/download PDF
36. Evidence that the Pim1 kinase gene is a direct target of HOXA9.
- Author
-
Hu YL, Passegué E, Fong S, Largman C, and Lawrence HJ
- Subjects
- Apoptosis, Bone Marrow Cells metabolism, Hematopoietic Stem Cells cytology, Humans, K562 Cells, Leukemia, Myeloid metabolism, Phosphorylation, RNA, Messenger metabolism, Retroviridae genetics, Time Factors, Transgenes, U937 Cells, Gene Expression Regulation, Enzymologic, Gene Expression Regulation, Leukemic, Homeodomain Proteins metabolism, Proto-Oncogene Proteins c-pim-1 metabolism
- Abstract
The HOXA9 homeoprotein exerts dramatic effects in hematopoiesis. Enforced expression of HOXA9 enhances proliferation of primitive blood cells, expands hematopoietic stem cells (HSCs), and leads to myeloid leukemia. Conversely, loss of HOXA9 inhibits proliferation and impairs HSC function. The pathways by which HOXA9 acts are largely unknown, and although HOXA9 is a transcription factor, few direct target genes have been identified. Our previous study suggested that HOXA9 positively regulates Pim1, an oncogenic kinase. The hematologic phenotypes of Hoxa9- and Pim1-deficient animals are strikingly similar. Here we show that HOXA9 protein binds to the Pim1 promoter and induces Pim1 mRNA and protein in hematopoietic cells. Pim1 protein is diminished in Hoxa9(-/-) cells, and Hoxa9 and Pim1 mRNA levels track together in early hematopoietic compartments. Induction of Pim1 protein by HOXA9 increases the phosphorylation and inactivation of the proapoptotic BAD protein, a target of Pim1. Hoxa9(-/-) cells show increased apoptosis and decreased proliferation, defects that are ameliorated by reintroduction of Pim1. Thus Pim1 appears to be a direct transcriptional target of HOXA9 and a mediator of its antiapoptotic and proproliferative effects in early cells. Since HOXA9 is frequently up-regulated in acute myeloid leukemia, Pim1 may be a therapeutic target in human disease.
- Published
- 2007
- Full Text
- View/download PDF
37. Simultaneous presence of major secondary chromosomal abnormalities in blast crisis of chronic myeloid leukemia.
- Author
-
Lu CM, Wang E, and Lawrence HJ
- Subjects
- Blast Crisis pathology, Humans, Leukemia, Myelogenous, Chronic, BCR-ABL Positive pathology, Male, Middle Aged, Philadelphia Chromosome, Trisomy genetics, Blast Crisis genetics, Chromosome Aberrations, Leukemia, Myelogenous, Chronic, BCR-ABL Positive genetics
- Published
- 2007
- Full Text
- View/download PDF
38. Analysis of HSC activity and compensatory Hox gene expression profile in Hoxb cluster mutant fetal liver cells.
- Author
-
Bijl J, Thompson A, Ramirez-Solis R, Krosl J, Grier DG, Lawrence HJ, and Sauvageau G
- Subjects
- Animals, Cell Count, Liver metabolism, Mice, Mice, Inbred C57BL, Mice, Knockout, Mutation, Reverse Transcriptase Polymerase Chain Reaction methods, Transcription Factors deficiency, Gene Expression Profiling, Hematopoietic Stem Cells cytology, Hematopoietic Stem Cells metabolism, Homeodomain Proteins genetics, Liver cytology, Liver embryology, Transcription Factors genetics
- Abstract
Overexpression of Hoxb4 in bone marrow cells promotes expansion of hematopoietic stem cell (HSC) populations in vivo and in vitro, indicating that this homeoprotein can activate the genetic program that determines self-renewal. However, this function cannot be solely attributed to Hoxb4 because Hoxb4(-/-) mice are viable and have an apparently normal HSC number. Quantitative polymerase chain reaction analysis showed that Hoxb4(-/-) c-Kit+ fetal liver cells expressed moderately higher levels of several Hoxb cluster genes than control cells, raising the possibility that normal HSC activity in Hoxb4(-/-) mice is due to a compensatory up-regulation of other Hoxb genes. In this study, we investigated the competitive repopulation potential of HSCs lacking Hoxb4 alone, or in conjunction with 8 other Hoxb genes. Our results show that Hoxb4(-/-) and Hoxb1-b9 (-/-) fetal liver cells retain full competitive repopulation potential and the ability to regenerate all myeloid and lymphoid lineages. Quantitative Hox gene expression profiling in purified c-Kit+ Hoxb1-b9(-/-) fetal liver cells revealed an interaction between the Hoxa, b, and c clusters with variation in expression levels of Hoxa4,-a11, and -c4.Together, these studies show a complex network of genetic interactions between several Hox genes in primitive hematopoietic cells and demonstrate that HSCs lacking up to 30% of the active Hox genes remain fully competent.
- Published
- 2006
- Full Text
- View/download PDF
39. Loss of expression of the Hoxa-9 homeobox gene impairs the proliferation and repopulating ability of hematopoietic stem cells.
- Author
-
Lawrence HJ, Christensen J, Fong S, Hu YL, Weissman I, Sauvageau G, Humphries RK, and Largman C
- Subjects
- Animals, Cell Movement physiology, Cell Proliferation, Flow Cytometry, Gene Expression, Hematopoiesis genetics, Mice, Mice, Mutant Strains, Bone Marrow Cells cytology, Bone Marrow Cells metabolism, Hematopoietic Stem Cells cytology, Hematopoietic Stem Cells metabolism, Homeodomain Proteins genetics, Homeodomain Proteins metabolism
- Abstract
The homeobox gene Hoxa-9 is normally expressed in primitive bone marrow cells, and overexpression of Hoxa-9 markedly expands hematopoietic stem cells, suggesting a function in early hematopoiesis. We present evidence for major functional defects in Hoxa-9-/- hematopoietic stem cells. Hoxa-9-/- marrow cells have normal numbers of immunophenotypic stem cells (Lin(-)c-kit(+)flk-2(-)Sca-1+ [KLFS] cells). However, sublethally irradiated Hoxa-9-/- mice develop persistent pancytopenia, indicating unusual sensitivity to ionizing irradiation. In competitive transplantation assays, Hoxa-9-/- cells showed an 8-fold reduction in multilineage long-term repopulating ability, a defect not seen in marrow cells deficient for the adjacent Hoxa-10 gene. Single-cell cultures of KLFS cells showed a 4-fold reduction in large high-proliferation potential colonies. In liquid cultures, Hoxa-9-deficient Lin(-)Sca-1(+) cells showed slowed proliferation (a 5-fold reduction in cell numbers at day 8) and delayed emergence of committed progenitors (a 5-fold decrease in colony-forming cells). Slowing of proliferation was accompanied by a delay in myeloid maturation, with a decrease in Gr-1hiMac-1hi cells at the end of the culture. Retroviral transduction with a Hoxa-9 expression vector dramatically enhanced the cytokine-driven proliferation and in vivo engraftment of Hoxa-9-/- marrow cells. Hoxa-9 appears to be specifically required for normal hematopoietic stem cell function both in vitro and in vivo.
- Published
- 2005
- Full Text
- View/download PDF
40. HOX genes: not just myeloid oncogenes any more.
- Author
-
Lawrence HJ, Fischbach NA, and Largman C
- Subjects
- Animals, Gene Expression Regulation, Neoplastic, Humans, Leukemia, Myeloid etiology, Genes, Homeobox, Leukemia, Myeloid genetics
- Published
- 2005
- Full Text
- View/download PDF
41. Activation of stem-cell specific genes by HOXA9 and HOXA10 homeodomain proteins in CD34+ human cord blood cells.
- Author
-
Ferrell CM, Dorsam ST, Ohta H, Humphries RK, Derynck MK, Haqq C, Largman C, and Lawrence HJ
- Subjects
- Animals, Cells, Cultured, Fetal Blood cytology, Gene Expression Profiling, Hematopoietic Stem Cells cytology, Homeobox A10 Proteins, Humans, Mice, Oligonucleotide Array Sequence Analysis, Antigens, CD34, Fetal Blood physiology, Hematopoietic Stem Cells metabolism, Homeodomain Proteins biosynthesis, Up-Regulation physiology
- Abstract
There is growing evidence for a role of HOX homeodomain proteins in normal hematopoiesis. Several HOX genes, including HOXA9 and HOXA10, are expressed in primitive hematopoietic cells, implying a role in early hematopoietic differentiation. To identify potential target genes of these two closely related transcription factors, human CD34+ umbilical cord blood cells were transduced with vectors expressing either HOXA9 or HOXA10 and analyzed with cDNA micro-arrays. Statistical analysis using significance analysis of microarrays revealed a common signature of several hundred genes, demonstrating that the transcriptomes of HOXA9 and HOXA10 largely overlap in this cellular context. Seven genes that were upregulated by both HOX proteins were validated by real-time reverse transcription polymerase chain reaction. HOXA9 and HOXA10 showed positive regulation of genes in the Wnt pathway, including Wnt10B and two Wnt receptors Frizzled 1 and Frizzled 5, an important pathway for hematopoietic stem cell (HSC) self-renewal. Other validated genes included v-ets-related gene (ERG), Iroquois 3 (IRX3), aldehyde dehydrogenase 1 (ALDH1), and very long-chain acyl-CoA synthetase homolog 1 (VLCS-H1). GenMAPP (Gene Micro Array Pathway Profiler) analysis indicated that HOXA10 repressed expression of several genes involved in heme biosynthesis and three globin genes, indicating a general suppression of erythroid differentiation. A number of genes regulated by HOXA9 and HOXA10 are expressed in normal HSC populations.
- Published
- 2005
- Full Text
- View/download PDF
42. HOXB6 overexpression in murine bone marrow immortalizes a myelomonocytic precursor in vitro and causes hematopoietic stem cell expansion and acute myeloid leukemia in vivo.
- Author
-
Fischbach NA, Rozenfeld S, Shen W, Fong S, Chrobak D, Ginzinger D, Kogan SC, Radhakrishnan A, Le Beau MM, Largman C, and Lawrence HJ
- Subjects
- Acute Disease, Animals, Cell Differentiation genetics, Cell Line, Transformed, Cell Proliferation, Erythropoiesis genetics, Female, Homeodomain Proteins physiology, Karyotyping, Leukemia, Myeloid genetics, Leukemia, Myeloid pathology, Lymphopoiesis genetics, Mice, Mice, Congenic, Mice, Inbred C57BL, Myeloid Ecotropic Viral Integration Site 1 Protein, Neoplasm Proteins physiology, Phenotype, Time Factors, Bone Marrow Cells metabolism, Bone Marrow Cells pathology, Cell Transformation, Neoplastic pathology, Homeodomain Proteins biosynthesis, Homeodomain Proteins genetics, Leukemia, Myeloid blood, Myeloid Progenitor Cells metabolism, Myeloid Progenitor Cells pathology
- Abstract
The HOX family of homeobox genes plays an important role in normal and malignant hematopoiesis. Dysregulated HOX gene expression profoundly effects the proliferation and differentiation of hematopoietic stem cells (HSCs) and committed progenitors, and aberrant activation of HOX genes is a common event in human myeloid leukemia. HOXB6 is frequently overexpressed in human acute myeloid leukemia (AML). To gain further insight into the role of HOXB6 in hematopoiesis, we overexpressed HOXB6 in murine bone marrow using retrovirus-mediated gene transfer. We also explored structure-function relationships using mutant HOXB6 proteins unable to bind to DNA or a key HOX-binding partner, pre-B-cell leukemia transcription factor-1 (PBX1). Additionally, we investigated the potential cooperative interaction with myeloid ecotropic viral integration site 1 homolog (MEIS1). In vivo, HOXB6 expanded HSCs and myeloid precursors while inhibiting erythropoiesis and lymphopoiesis. Overexpression of HOXB6 resulted in AML with a median latency of 223 days. Coexpression of MEIS1 dramatically shortened the onset of AML. Cytogenetic analysis of a subset of HOXB6-induced AMLs revealed recurrent deletions of chromosome bands 2D-E4, a region frequently deleted in HOXA9-induced AMLs. In vitro, HOXB6 immortalized a factor-dependent myelomonocytic precursor capable of granulocytic and monocytic differentiation. These biologic effects of HOXB6 were largely dependent on DNA binding but independent of direct interaction with PBX1.
- Published
- 2005
- Full Text
- View/download PDF
43. Surgical management of gallbladder mucoceles in dogs: 22 cases (1999-2003).
- Author
-
Worley DR, Hottinger HA, and Lawrence HJ
- Subjects
- Animals, Dog Diseases pathology, Dogs, Female, Gallbladder Diseases complications, Gallbladder Diseases pathology, Gallbladder Diseases surgery, Liver pathology, Liver Diseases diagnosis, Liver Diseases pathology, Liver Diseases veterinary, Male, Mucocele complications, Mucocele pathology, Mucocele surgery, Pancreatitis diagnosis, Pancreatitis pathology, Pancreatitis veterinary, Prognosis, Retrospective Studies, Treatment Outcome, Dog Diseases surgery, Gallbladder Diseases veterinary, Mucocele veterinary
- Abstract
Objectives: To describe preoperative, surgical, and postoperative findings and determine prognostic indicators and treatment recommendations in dogs treated surgically for gallbladder mucocele., Design: Retrospective study., Animals: 22 client-owned dogs., Procedures: Medical records of dogs with gallbladder mucoceles that were treated surgically were reviewed. History, clinical signs, results of selected clinicopathologic analyses and abdominal ultrasonography, surgical procedure performed, results of histologic examination of a liver biopsy specimen, and survival time were recorded. Follow-up information was obtained via telephone interview with owners and referring veterinarians., Results: Dogs were 7 to 15 years of age and had non-specific clinical signs (vomiting, anorexia, and lethargy). Physical examination findings included icterus, signs of depression, and signs of discomfort on palpation of the abdomen. Sixteen dogs had a definitive diagnosis and 6 dogs were strongly suspected of having a gallbladder mucocele on the basis of results of abdominal ultrasonography. Fifteen dogs survived after surgery; 3 of these dogs had bile-induced peritonitis, and 4 had pancreatitis. One dog was euthanatized as a result of severe pancreatitis, and 1 was euthanatized because of acute renal failure; 5 dogs died as a result of pancreatitis, cholecystitis, or bile-induced peritonitis. Hepatic abnormalities were detected histologically in all dogs., Conclusions and Clinical Relevance: No predictors of survival were identified. No associations between outcome of surgical treatment (survival vs nonsurvival) and preoperative findings, biliary rupture, surgical procedure performed, results of histologic examination of the liver, or development of pancreatitis were found. Cholecystoduodenostomy and cholecystectomy appear to be acceptable treatments for gallbladder mucocele.
- Published
- 2004
- Full Text
- View/download PDF
44. HOXB6 protein is bound to CREB-binding protein and represses globin expression in a DNA binding-dependent, PBX interaction-independent process.
- Author
-
Shen W, Chrobak D, Krishnan K, Lawrence HJ, and Largman C
- Subjects
- Acetyltransferases metabolism, Animals, CREB-Binding Protein, DNA metabolism, Gene Expression Regulation, Developmental, Histone Acetyltransferases, Homeodomain Proteins chemistry, Humans, K562 Cells, Liver cytology, Mice, Precipitin Tests, Protein Structure, Secondary, Protein Structure, Tertiary, RNA, Messenger metabolism, Serine genetics, Transfection, Globins genetics, Homeodomain Proteins genetics, Homeodomain Proteins metabolism, Nuclear Proteins metabolism, Trans-Activators metabolism
- Abstract
Although HOXB6 and other HOX genes have previously been associated with hematopoiesis and leukemias, the precise mechanism of action of their protein products remains unclear. Here we use a biological model in which HOXB6 represses alpha- and gamma-globin mRNA levels to perform a structure/function analysis for this homeodomain protein. HOXB6 protein represses globin transcript levels in stably transfected K562 cells in a DNA-binding dependent fashion. However, the capacity to form cooperative DNA-binding complexes with the PBX co-factor protein is not required for HOXB6 biological activity. Neither the conserved extreme N-terminal region, a polyglutamic acid region at the protein C terminus, nor the Ser(214) CKII phosphorylation site was required for DNA binding or activity in this model. We have previously reported that HOX proteins can inhibit CREB-binding protein (CBP)-histone acetyltransferase-mediated potentiation of reporter gene transcription. We now show that endogenous CBP is co-precipitated with exogenous HOXB6 from nuclear and cytoplasmic compartments of transfected K562 cells. Furthermore, endogenous CBP co-precipitates with endogenous HOXB6 in day 14.5 murine fetal liver cells during active globin gene expression in this tissue. The CBP interaction motif was localized to the homeodomain but does not require the highly conserved helix 3. Our data suggest that the homeodomain contains most or all of the important structures required for HOXB6 activity in blood cells.
- Published
- 2004
- Full Text
- View/download PDF
45. Protein kinase C-mediated phosphorylation of the leukemia-associated HOXA9 protein impairs its DNA binding ability and induces myeloid differentiation.
- Author
-
Vijapurkar U, Fischbach N, Shen W, Brandts C, Stokoe D, Lawrence HJ, and Largman C
- Subjects
- Amino Acid Sequence, Animals, Bone Marrow Cells cytology, Bone Marrow Cells physiology, Casein Kinase II, Cell Line, Enzyme Activation, Isoenzymes metabolism, Leukemia, Myeloid, Mice, Molecular Sequence Data, Myeloid Cells cytology, Phorbol Esters metabolism, Phosphorylation, Protein Binding, Protein Kinase C antagonists & inhibitors, Protein Serine-Threonine Kinases metabolism, Serine metabolism, Cell Differentiation physiology, DNA-Binding Proteins metabolism, Homeodomain Proteins metabolism, Myeloid Cells physiology, Protein Kinase C metabolism
- Abstract
HOXA9 expression is a common feature of acute myeloid leukemia, and high-level expression is correlated with poor prognosis. Moreover, HOXA9 overexpression immortalizes murine marrow progenitors that are arrested at a promyelocytic stage of differentiation when cultured and causes leukemia in recipient mice following transplantation of HOXA9 expressing bone marrow. The molecular mechanisms underlying the physiologic functions and transforming properties of HOXA9 are poorly understood. This study demonstrates that HOXA9 is phosphorylated by protein kinase C (PKC) and casein kinase II and that PKC mediates phosphorylation of purified HOXA9 on S204 as well as on T205, within a highly conserved consensus sequence, in the N-terminal region of the homeodomain. S204 in the endogenous HOXA9 protein was phosphorylated in PLB985 myeloid cells, as well as in HOXA9-immortalized murine marrow cells. This phosphorylation was enhanced by phorbol ester, a known inducer of PKC, and was inhibited by a specific PKC inhibitor. PKC-mediated phosphorylation of S204 decreased HOXA9 DNA binding affinity in vitro and the ability of the endogenous HOXA9 to form cooperative DNA binding complexes with PBX. PKC inhibition significantly reduced the phorbol-ester induced differentiation of the PLB985 hematopoietic cell line as well as HOXA9-immortalized murine bone marrow cells. These data suggest that phorbol ester-induced myeloid differentiation is in part due to PKC-mediated phosphorylation of HOXA9, which decreases the DNA binding of the homeoprotein.
- Published
- 2004
- Full Text
- View/download PDF
46. Use of gabapentin in the prevention of taxane-induced arthralgias and myalgias.
- Author
-
Nguyen VH and Lawrence HJ
- Subjects
- Acetates administration & dosage, Analgesics administration & dosage, Antineoplastic Agents, Phytogenic therapeutic use, Docetaxel, Gabapentin, Humans, Muscle, Skeletal pathology, Paclitaxel therapeutic use, Retrospective Studies, Taxoids therapeutic use, Acetates therapeutic use, Amines, Analgesics therapeutic use, Antineoplastic Agents, Phytogenic adverse effects, Arthralgia chemically induced, Arthralgia prevention & control, Cyclohexanecarboxylic Acids, Muscular Diseases chemically induced, Muscular Diseases prevention & control, Paclitaxel adverse effects, Taxoids adverse effects, gamma-Aminobutyric Acid
- Published
- 2004
- Full Text
- View/download PDF
47. The transcriptome of the leukemogenic homeoprotein HOXA9 in human hematopoietic cells.
- Author
-
Dorsam ST, Ferrell CM, Dorsam GP, Derynck MK, Vijapurkar U, Khodabakhsh D, Pau B, Bernstein H, Haqq CM, Largman C, and Lawrence HJ
- Subjects
- Blotting, Western, Bone Marrow Cells cytology, Cell Division, DNA chemistry, DNA, Complementary metabolism, Down-Regulation, Homeodomain Proteins genetics, Humans, Jurkat Cells, K562 Cells, Leukemia genetics, Luciferases metabolism, Oligonucleotide Array Sequence Analysis, Reverse Transcriptase Polymerase Chain Reaction, Transcription, Genetic, Transfection, U937 Cells, Up-Regulation, Gene Expression Regulation, Hematopoietic Stem Cells metabolism, Homeodomain Proteins biosynthesis, Leukemia metabolism, RNA, Messenger metabolism
- Abstract
Hematopoietic defects in HOXA9(-/-) mice demonstrate a key role for this homeoprotein in blood cell development. Conversely, enforced HOXA9 expression is leukemogenic in mice, and HOXA9 is frequently activated in human acute myeloid leukemia (AML). Although HOXA9 is thought to function as a transcription factor, few downstream targets have been identified. We searched for early HOXA9 target genes by using a transient overexpression strategy in 3 hematopoietic cell lines (2 myeloid, 1 lymphoid). cDNA microarray analyses identified 220 genes whose expression was modulated at least 2-fold. Expression signatures in myeloid and lymphoid cells demonstrated that HOXA9 functions as both an activator and repressor of a variety of genes in cell-specific patterns suggesting that the transcriptional effects of HOXA9 are largely dependent on the cell context. Transient transcription assays and target gene expression patterns in HOXA9(-/-) marrow cells imply that we have identified direct physiologic targets. Many target genes are expressed in CD34+ stem cells or are members of gene families involved in proliferation or myeloid differentiation. Expression of 14 HOXA9 target genes correlated with high-level HOXA9 expression in primary AML. These data suggest that many genes identified in this survey may mediate the biologic effects of HOXA9 in normal and leukemic hematopoiesis.
- Published
- 2004
- Full Text
- View/download PDF
48. Measuring stem cell frequency in epidermis: a quantitative in vivo functional assay for long-term repopulating cells.
- Author
-
Schneider TE, Barland C, Alex AM, Mancianti ML, Lu Y, Cleaver JE, Lawrence HJ, and Ghadially R
- Subjects
- Animals, Animals, Newborn, Mice, Mice, SCID, Cell Lineage, Stem Cells cytology
- Abstract
Epidermal stem cells play a central role in tissue homeostasis, wound repair, tumor initiation, and gene therapy. A major impediment to the purification and molecular characterization of epidermal stem cells is the lack of a quantitative assay for cells capable of long-term repopulation in vivo, such as exists for hematopoietic cells. The tremendous strides made in the characterization and purification of hematopoietic stem cells have been critically dependent on the availability of competitive transplantation assays, because these assays permit the accurate quantitation of long-term repopulating cells in vivo. We have developed an analogous functional assay for epidermal stem cells, and have measured the frequency of functional epidermal stem cells in interfollicular epidermis. These studies indicate that cells capable of long-term reconstitution of a squamous epithelium reside in the interfollicular epidermis. We find that the frequency of these long-term repopulating cells is 1 in 35,000 total epidermal cells, or in the order of 1 in 104 basal epidermal cells, similar to that of hematopoietic stem cells in the bone marrow, and much lower than previously estimated in epidermis. Furthermore, these studies establish a novel functional assay that can be used to validate immunophenotypic markers and enrichment strategies for epidermal stem cells, and to quantify epidermal stem cells in various keratinocyte populations. Thus further studies using this type of assay for epidermis should aid in the progress of cutaneous stem cell-targeted gene therapy, and in more basic studies of epidermal stem cell regulation and differentiation.
- Published
- 2003
- Full Text
- View/download PDF
49. Overexpression of the myeloid leukemia-associated Hoxa9 gene in bone marrow cells induces stem cell expansion.
- Author
-
Thorsteinsdottir U, Mamo A, Kroon E, Jerome L, Bijl J, Lawrence HJ, Humphries K, and Sauvageau G
- Subjects
- Animals, B-Lymphocytes pathology, Bone Marrow Cells pathology, Cell Count, Cell Division, Gene Expression Regulation, Granulocytes, Hematopoiesis, Hematopoietic Stem Cells pathology, Leukemia, Myeloid, Acute pathology, Mice, Mice, Inbred C3H, Mice, Inbred C57BL, Mice, Transgenic, Retroviridae genetics, T-Lymphocytes pathology, Transfection, Transplantation Chimera, Bone Marrow Cells metabolism, Gene Expression, Hematopoietic Stem Cells metabolism, Homeodomain Proteins genetics, Leukemia, Myeloid, Acute genetics, Neoplasm Proteins genetics
- Abstract
Cytogenetic, genetic, and functional studies have demonstrated a direct link between deregulated Hoxa9 expression and acute myeloid leukemia (AML). Hoxa9 overexpression in mouse bone marrow cells invariably leads to AML within 3 to 10 months, suggesting the requirement for additional genetic events prior to AML. To gain further insight into how Hoxa9 affects hematopoietic development at the preleukemic stage, we have engineered its overexpression (1) in hematopoietic stem cells using retrovirus-mediated gene transfer and generated bone marrow transplantation chimeras and (2) in lymphoid cells using transgenic mice. Compared with controls, recipients of Hoxa9-transduced cells had an about 15-fold increase in transplantable lymphomyeloid long-term repopulating cells, indicating the capacity for this oncogene to confer a growth advantage to hematopoietic stem cells. In addition, overexpression of Hoxa9 in more mature cells enhanced granulopoiesis and partially blocked B lymphopoiesis at the pre-B-cell stage but had no detectable effect on T lymphoid development. Interestingly, despite specifically directing high expression of Hoxa9 in T and B lymphoid lineages, none of the Hoxa9 transgenic mice developed lymphoid malignancies for the observation period of more than 18 months.
- Published
- 2002
- Full Text
- View/download PDF
50. Differential expression of Hox, Meis1, and Pbx1 genes in primitive cells throughout murine hematopoietic ontogeny.
- Author
-
Pineault N, Helgason CD, Lawrence HJ, and Humphries RK
- Subjects
- Animals, Cell Differentiation genetics, Cell Lineage genetics, Mice, Mice, Inbred C57BL, Myeloid Ecotropic Viral Integration Site 1 Protein, Pre-B-Cell Leukemia Transcription Factor 1, DNA-Binding Proteins genetics, Gene Expression Regulation, Hematopoiesis genetics, Hematopoietic Stem Cells physiology, Homeodomain Proteins genetics, Neoplasm Proteins genetics, Proto-Oncogene Proteins genetics
- Abstract
Objective: The Hox gene family of transcription factors is thought to be involved in the regulation of primitive hematopoietic cells, including stem cells and early committed progenitors, and has also been directly implicated in leukemia. To gain further insight into Hox gene-mediated regulation of hematopoiesis, we investigated the expression pattern of representative Hox genes and two of their cofactors, Pbx1 and Meis1, at different stages of murine hematopoiesis., Methods: Functionally distinct subpopulations of murine bone marrow (BM) and fetal liver day 14.5 (FL) cells were isolated by flow cytometry, and gene expression of various homeobox-containing genes was assessed by global cDNA amplification technique., Results: Hox genes were found preferentially expressed in hematopoietic stem cell (HSC)-enriched subpopulations and downregulated following differentiation and maturation. This profile of expression was observed at both adult and fetal stages of hematopoiesis. The Pbx1 and Meis1 genes had important differences in their expression pattern but were both detected in Hox expressing subpopulations. In particular, Meis1 consistently showed an expression profile closely resembling that of Hox genes. Finally, using the in vitro embryonic stem (ES) cell differentiation model to mimic embryonic hematopoiesis, we found coexpression of Hox genes and their cofactors coincided with the appearance of hematopoietic progenitor cells., Conclusion: Together, these results further support the notion that Hox genes are involved in the regulation of early hematopoietic cells and provide strong evidence that they are involved in the regulation of hematopoiesis throughout ontogeny.
- Published
- 2002
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.